Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
e-Letters: Comments and Responses

Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake

  1. Katrine M. Lauritsen1,2,
  2. Esben Søndergaard1,2,3,
  3. Mads Svart1,2,
  4. Niels Møller1,3 and
  5. Lars C. Gormsen4⇑
  1. 1Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
  2. 2Danish Diabetes Academy, Odense University Hospital, Odense, Denmark
  3. 3Steno Diabetes Center Aarhus, Aarhus, Denmark
  4. 4Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark
  1. Corresponding author: Lars C. Gormsen, lars.christian.gormsen{at}clin.au.dk.
Diabetes Care 2018 Dec; 41(12): e152-e154. https://doi.org/10.2337/dc18-1421
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Sodium–glucose cotransporter 2 (SGLT2) inhibition was originally developed as a facile way of lowering blood glucose through increased renal elimination. However, clinical trials have demonstrated that SGLT2 inhibition not only improves glycemic control but also increases circulating ketone bodies and hematocrit (1,2). Recently, SGLT2 inhibitor–driven modest hyperketonemia has attracted much focus as a possible explanation of the improved cardiac outcome in patients treated with SGLT2 inhibitors (3), whereas the increased hematocrit has mostly been ascribed to hemoconcentration due to increased osmotic diuresis. In this Observation, we present data indicating that hyperketonemia directly stimulates circulating erythropoietin concentrations and is associated with increased bone marrow activity assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT).

Seventeen healthy subjects undergoing either cardiac (study A) or brain (study B) PET/CT as part of protocols involving experimental hyperketonemia were investigated. Study A (4) consisted of 8 subjects (3 women) aged mean 60 (range 50–68) years with BMI mean 26 (range 22–35) kg/m2, and study B (5) of 9 subjects (4 women) aged 62 (56–69) years with BMI 24 (21–27) kg/m2. Both studies were randomized, single-blinded crossover trials in which participants were infused with either 7.5% Na-3-β-hydroxybutyrate (3-OHB) (infusion rate 0.18 g/kg/h [study A] and 0.22 g/kg/h [study B]) or saline (0.9%). In study A, bone marrow palmitate and glucose uptake was measured with dynamic 11C-palmitate and 18F-FDG PET (n = 8). Bone marrow time-radioactivity curves were measured in two vertebrae in the spine, and the input function was derived from either arterial samples (11C-palmitate) or from a volume of interest drawn in the aorta (18F-FDG). Uptake rates were obtained using linear graphical analysis (Logan plot for 18F-FDG and Patlak analysis for 11C-palmitate).

A serum sample from the end of each study day (study A: t = 390 min, study B: t = 240 min) was analyzed for erythropoietin by a chemiluminescent immunoassay on Immulite 2000 (Siemens Healthineers, Erlangen, Germany).

By design, 3-OHB concentrations increased rapidly during ketone body infusions (Fig. 1A), reaching mean ± SEM 3.8 ± 0.2 mmol/L (study A) and 5.5 ± 0.4 mmol/L (study B). Ketone body levels were undetectable on saline study days.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

A: 3-OHB concentrations during hyperketonemia (open boxes) and saline (closed circles). Error bars are SEM. EPO, erythropoietin. B: Representative CT and PET images (coronal and axial projections) of subject no. 8 on the ketone body infusion study day. PET images were summed from 5–50 min and represent average standardized uptake values (SUV). As seen, the bone marrow was clearly visible. C: Erythropoietin levels. D: Bone marrow glucose uptake (volume of distribution) assessed by 18F-FDG PET/CT.

As seen in Fig. 1C, erythropoietin concentrations were significantly greater during hyperketonemia than after saline infusions (mean ± SD 9.9 ± 1.1 vs. 7.6 ± 1.0 IU/L, P = 0.01). Hyperketonemia was also associated with 25% increased bone marrow 18F-FDG uptake compared with the saline study day (mean ± SD 0.64 ± 0.08 vs. 0.51 ± 0.12 mL plasma/mL tissue, P = 0.04) (Fig. 1D) but did not affect bone marrow 11C-palmitate uptake (1.7 ± 0.4 vs. 1.9 ± 0.6 µmol/g/min, P = 0.62). No correlation was observed between the increase in erythropoietin concentration and increase in bone marrow glucose uptake (r = −0.09, P = 0.84).

Some data supporting a connection between ketone bodies and erythropoietin exist. Thus, it has been shown that the hematocrit of infants born to mothers with diabetes is correlated with maternal 3-OHB concentrations and also that 4 weeks of SGLT2 inhibition by empagliflozin results in both increased levels of ketone bodies and a most-likely-transient increase in erythropoietin (2). In addition, dapagliflozin treatment causes not only hemoconcentration but also increased total red cell mass and transient increases in reticulocytes and erythropoietin.

Although the levels of hyperketonemia obtained in our experimental protocols were markedly greater than what has been observed during SGLT2 inhibitor treatment (4–5 vs. ∼0.6 mmol/L) (3), it is possible that a more modest but sustained increase in ketone bodies has a similar effect on erythropoietin levels. Erythropoietin is primarily produced in specialized renal cells, and increased secretion of the hormone in response to, e.g., altitude-induced hypoxia is not necessarily closely related to the stimulus. In other words, we may have only detected the initial increase in erythropoietin levels that the experimental hyperketonemia would eventually have produced.

Erythropoietin stimulates red blood cell maturation and release from the bone marrow, an energy-consuming process visible as avid 18F-FDG uptake on PET/CT. The time to maximum effect of a single dose of human recombinant erythropoietin on reticulocyte cell count is 200–300 h, and it is therefore not surprising that we were unable to demonstrate a correlation between erythropoietin levels and bone marrow activity. Alternatively, the increase in bone marrow glucose uptake could be the result of increased leukopoiesis or thrombopoiesis or increased blood flow. We find this unlikely since 1) ketone bodies have been reported to be anti-inflammatory, 2) it takes several weeks of ketone body ingestion to increase thrombocytes discretely, and 3) bone marrow 11C-palmitate uptake was unaffected.

In conclusion, experimental hyperketonemia results in ∼30% concomitant increase in erythropoietin levels and bone marrow glucose uptake. Although the level of hyperketonemia in our study was markedly higher than what is typically observed during SGLT2 inhibition, our data provide a possible explanation for the unknown link between SGLT2 inhibitor treatment and increased erythropoiesis.

Acknowledgments

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Funding. The study was supported by grants from the Danish Council for Strategic Research, the Danish Council for Independent Research | Medical Sciences, Aase Danielsen Fund, Ferd. og Ellen Hindsgauls Fund, the Danish Medical Association, the Novo Nordisk Foundation, the Danish Diabetes Association, the Danish Diabetes Academy supported by the Novo Nordisk Foundation, the Health Research Fund of Central Denmark Region, and the A.P. Møller Foundation.

Author Contributions. N.M. and L.C.G. conceptualized the study and wrote the protocol. K.M.L., E.S., M.S., and L.C.G. researched the data. E.S. contributed to discussion. K.M.L. wrote the manuscript, and E.S., M.S., N.M., and L.C.G. reviewed and edited the manuscript. N.M. and L.C.G. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

  • Clinical trial reg. nos. NCT02814474 (study A) and NCT02357550 (study B), clinicaltrials.gov.

  • Received July 3, 2018.
  • Accepted September 4, 2018.
  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Zinman B,
    2. Wanner C,
    3. Lachin JM, et al.; EMPA-REG OUTCOME Investigators
    . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ferrannini E,
    2. Baldi S,
    3. Frascerra S, et al
    . Renal handling of ketones in response to sodium–glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2017;40:771–776
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Ferrannini E,
    2. Mark M,
    3. Mayoux E
    . CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 2016;39:1108–1114
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Gormsen LC,
    2. Svart M,
    3. Thomsen HH, et al
    . Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc 2017;6:e005066
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Svart M,
    2. Gormsen LC,
    3. Hansen J, et al
    . Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial. PLoS One 2018;13:e0190556
    OpenUrl
View Abstract
PreviousNext
Back to top
Diabetes Care: 41 (12)

In this Issue

December 2018, 41(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake
Katrine M. Lauritsen, Esben Søndergaard, Mads Svart, Niels Møller, Lars C. Gormsen
Diabetes Care Dec 2018, 41 (12) e152-e154; DOI: 10.2337/dc18-1421

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Ketone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake
Katrine M. Lauritsen, Esben Søndergaard, Mads Svart, Niels Møller, Lars C. Gormsen
Diabetes Care Dec 2018, 41 (12) e152-e154; DOI: 10.2337/dc18-1421
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Response to Comment on Cho et al. Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer–Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. Diabetes Care 2019;42:1675–1683
  • Response to Comment on Kiviniemi et al. Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease: The ARTEMIS Study. Diabetes Care 2019;42:1319–1325
  • Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088–1094
Show more e-Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2019 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.